Expanding sales of Hanabiratake products, centered on the βeauty Glucan brand

「Because sales of “IT Hanabiratake” products were behind plan, net sales were nearly flat at ¥55 million, or 100.8% of the year-earlier period.」

「Although the company obtained a Foods with Function Claims notification number from the Consumer Affairs Agency for its “IT Hanabiratake” products in March 2025, customers held back on purchasing the old products during the lead time before the new product was launched in July. As a result, net sales were ¥104 million, or 99.4% of the year-earlier period.」

「As announced on 28 March 2025, after obtaining a Foods with Function Claims notification number from the Consumer Affairs Agency, the company will launch “EstroRich Pure,” a new product that clearly states the functionality of “IT Hanabiratake,” from the third quarter of fiscal 2025 onward, with the aim of expanding the business.」

「A decline in sales from OEM production of Hanabiratake products resulted in lower revenue of ¥105 million, or 73.2% of the year-earlier period.」

「Second-quarter net sales declined to ¥58 million, or 77.4% of the year-earlier period, owing to lower sales from OEM production of Hanabiratake products.」

「A decline in sales from OEM production of Hanabiratake products resulted in net sales of ¥31 million, or 82.0% of the year-earlier period, a decrease in revenue.」

「Focusing on Hanabiratake raw material sales to make up for delays in the initial plan resulted in an 8.7% year-on-year increase in net sales to ¥143 million.」

「Second-quarter net sales increased to ¥75 million, or 110.7% of the year-earlier period, owing to higher sales from OEM production of Hanabiratake products.」

「Higher OEM sales of Hanabiratake products increased net sales to ¥38 million, or 103.9% of the year-earlier period.」

「The publication in the academic journal Applied Pharmacology of a paper titled “Evaluation of the Efficacy and Safety of Hanabiratake in Relieving Unpleasant Symptoms of Menopause in Women” also increased inquiries about “IT Hanabiratake” from major health-food manufacturers, and the company is preparing for further sales growth.」

「As announced on 14 April 2022, a paper titled “Evaluation of the Efficacy and Safety of Hanabiratake in Relieving Unpleasant Symptoms of Menopause in Women” was published in the academic journal Applied Pharmacology. This also increased inquiries about “IT Hanabiratake” from major health-food manufacturers, and the company is preparing for further sales growth.」

「The supplements market addressing women’s health issues, known as the femcare market, is expanding. By promoting the benefits and efficacy of “IT Hanabiratake” to menopausal women, and with an increase in OEM transactions year on year, net sales increased to ¥36 million, or 106.6% of the year-earlier period.」

「During the consolidated fiscal year, performance was challenged by sluggish personal consumption amid the COVID-19 pandemic, and net sales were ¥130 million, or 67.6% of the previous fiscal year’s level.」

「As a result of selling the mail-order business during the previous second quarter and narrowing the range of products handled in order to focus on developing the business as a raw-materials manufacturer, net sales were ¥99 million, or 63.0% of the year-earlier period.」

「The market for supplements addressing women-specific health concerns is expanding. As a result of our active sales efforts to date, major companies have shown strong interest in Hanabiratake targeting menopausal women. By identifying the constituents of Hanabiratake, elucidating its mechanisms of action and promoting its efficacy, we aim to develop products in collaboration with major companies.」

「The sale of Intertrade Healthcare’s mail-order business, undertaken to focus on developing the business as a raw-materials manufacturer through products related to the “IT Hanabiratake” produced by the company, OEM products and raw material sales, resulted in net sales of ¥193 million, or 65.8% of the previous fiscal year’s level.」

「Following the sale of Intertrade Healthcare’s mail-order business in order to focus on developing the business as an “IT Hanabiratake” manufacturer, second-quarter net sales were ¥97 million, or 66.0% of the year-earlier period. However, separating the business with a deteriorating earnings structure and concentrating management resources led to a slight improvement in profitability, with the segment loss narrowing to ¥61 million from the previous year.」

「As a result of reviewing the business portfolio and narrowing the range of products handled in order to focus on developing the business as an “IT Hanabiratake” manufacturer, net sales were ¥54 million, or 67.2% of the previous year’s level.」

「Sales of products related to “IT maitake” produced by the company and possessing silent estrogen activity, including “EstroRich,” a supplement sold exclusively by 株式会社大木, a major pharmaceutical wholesaler, as well as OEM services and raw-material sales, remained firm. Revenue reached ¥293 million, or 114.0% of the previous fiscal year's level.」

「Sales of products related to “IT maitake” produced by the company and possessing silent estrogen activity, including “EstroRich,” a supplement sold exclusively by 株式会社大木, a major pharmaceutical wholesaler, as well as OEM services and raw-material sales, remained firm. Third-quarter revenue reached ¥223 million, or 114.6% of the year-earlier level.」

「Sales of products related to “IT maitake” produced by the company and possessing silent estrogen activity, including “EstroRich,” a supplement sold exclusively by 株式会社大木, a major pharmaceutical wholesaler, as well as OEM services and raw-material sales, remained firm. Second-quarter revenue reached ¥147 million, or 114.9% of the year-earlier level.」

「Sales of “EstroRich,” a supplement containing “IT maitake” produced by the company as an exclusive product of 株式会社大木, a major pharmaceutical wholesaler, were strong. Supplement sales to foreign customers also contributed, and first-quarter revenue reached ¥81 million, or 114.2% of the year-earlier level.」

「We actively sold the new product “IT Hanabiratake Furikake,” launched in January 2018, at department stores and other outlets and distributed it through channels that readily reach general consumers. We also began launching “EstroRich,” a supplement containing IT Hanabiratake, as an exclusive product of 株式会社大木, a major pharmaceutical wholesaler. As a result, Hanabiratake products accounted for a higher proportion of Healthcare sales.」

「We actively sold the new product “IT Hanabiratake Furikake,” launched in January 2018, at department stores and other outlets and distributed it through channels that readily reach general consumers. We also began launching “EstroRich,” a supplement containing IT Hanabiratake, as an exclusive product of 株式会社大木, a major pharmaceutical wholesaler. As a result, Hanabiratake products accounted for a higher proportion of Healthcare sales.」

「The new product “IT Hanabiratake Furikake,” launched in January 2018, was sold at department stores and other outlets. Distribution through channels that readily reach general consumers increased the proportion of Hanabiratake products in segment sales.」

「The research results for “IT maitake” produced by the company were recognized, and the product received Japan's first Superfood certification as an ingredient from the Japan Superfoods Association. It was also featured in Nikkei Trendy magazine as a notable ingredient for 2018, among other achievements that raised awareness.」

「These results were recognized, and our products were adopted for a new business of RIZAP株式会社, a major beauty and health company, including the Hanabiratake product “IT Hanabiratake” that we produce. This also helped raise awareness.」

「Through various initiatives, including focused sales of our own-brand products, sales of raw materials and OEM products launched in the previous fiscal year, and the rapid introduction of best-selling products, net sales increased 22.8% year on year.」

「We will expand sales of Hanabiratake-related supplements and cosmetics, centered on our group’s original “βeauty Glucan” brand.」